Navigation Links
Dr. Rongxiang Xu Receives the Prestigious Scroll Award from Los Angeles County Government
Date:10/31/2013

LOS ANGELES, Oct. 31, 2013 /PRNewswire/ -- Dr. Rongxiang Xu, a Los Angeles resident, received the prestigious Scroll Award from the Los Angeles county government on October 29, 2013 in the Kenneth Hahn Hall of Administration, for receiving the International Golden Biatec Award 2013 for his invention of organ regeneration science.  The Scroll Award was also given to Kevin Xu, Dr. Xu's son who is a California State Government Advisor, Young Entrepreneur Council member, CEO, and also supports and collaborates with Dr. Xu on his scientific research and developments.     

(Photo: http://photos.prnewswire.com/prnh/20131031/LA07829)

The awards were presented  by Supervisor Michael D. Antonovich, Los Angeles County Fifth District. Mr. Antonovich provided opening remarks stating "Today, we welcome Dr. Rongxiang Xu, recipient of the Golden Biatec award for his scientific work in the regeneration of human tissue (organ). Here today with Dr. Xu is his son Kevin Xu." He further commented that Dr. Xu is a renowned trauma burn surgeon and scientist who revolutionized the way doctors treat burn victims and replaced skin grafting with his inventive burns regenerative therapy; prior to the development of burns regenerative therapy, patients would have to endure painful skin graft surgery which resulted in lifelong scaring. By applying burns regenerative therapy, patients with deep degree burns can heal with little to no scaring by in situ skin regeneration, thereby avoiding the torture of skin graft. The route and solution of organ regeneration science invented by Dr. Xu has led the scientific community to believe that human tissues and organs could achieve in situ regeneration.

The European IEF Economic Club awarded Dr. Xu as the only foreign laureate of the International Golden Biatec 2013 for his invention of organ regeneration science and its route and solution. The Golden Biatec international award is a prestigious honor for international personalities who have made great contributions to mankind.  In the past, the Award has been given to 28 leaders of nations and world economy including Russian President Vladimir Putin, former U.S. President George W. Bush, and former President of France Jacques Chirac. Dr. Xu is the 29th international laureate of Golden Biatec. Rongxiang Xu delivered recently a landmark presentation during his awarding ceremony of Golden Biatec to declare that mankind is entering the era of applied organ regeneration science.

Contact:

Jane Westgate: 336-209-9276, Jane@westgatecom.com

Cheryl Riley: 703-683-1798, cherylrileypr@comcast.net


'/>"/>
SOURCE Dr. Rongxiang Xu
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Dr. Rongxiang Xu: a humanidade está entrando na nova era da Ciência Aplicada da Regeneração dos Órgãos
2. Dr. Rongxiang Xu: Mankind Is Entering New Era of Applied Organ Regeneration Science
3. Dr. Rongxiang Xu wird während seiner Auszeichnung mit dem internationalen Golden Biatec 2013 erklären, wie sich menschliche Organe selbst regenerieren können
4. Dr. Rongxiang Xu irá revelar como órgãos humanos podem alcançar a autorregeneração durante seu recebimento do prêmio Golden Biatec 2013 internacional
5. Dr. Rongxiang Xu to Reveal How Human Organs can Achieve Self-Regeneration during His Acceptance of the International Golden Biatec 2013 Award
6. Dr. Rongxiang Xu, Patent Owner of Damaged Organ Regeneration, a Top Priority Addressed in the 2013 Presidential State of The Union, Files Lawsuit Against Dr. Yamanaka for Deception
7. Dr. Rongxiang Xu, Patent Owner of Damaged Organ Regeneration, a Top Priority Addressed in the 2013 Presidential State of The Union, Files Lawsuit Against 2012 Nobel Laureate Dr. Yamanaka for Deception
8. Dr. Rongxiang Xu, Owner of Patented Technology to Regenerate Damaged Organs, Announces Lawsuit Against 2012 Nobel Laureate Dr. Shinya Yamanaka
9. Mainz University receives approval for an Alexander von Humboldt Professorship in Physics
10. Johns Hopkins Receives Prestigious ABET Accreditation for Its Part-time Master’s Degree in Systems Engineering
11. Ameritox Receives Accreditation from College of American Pathologists
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... ... January 18, 2017 , ... Total Orthopedics ... implanted SpineFrontier’s A-CIFT™ Solofuse-P™. The operation took place on Wednesday, January 11, 2017 ... procedure was an anterior cervical discectomy and fusion on a 42 year old ...
(Date:1/18/2017)... ... ... from a new study are stating that if levels of the blood test called ... there is still remaining prostate cancer cells that are more likely to come back, spreading ... an indicator of whether a man’s prostate cancer is growing or not,” stated Dr. ...
(Date:1/18/2017)... ... January 18, 2017 , ... Thirty-six startup companies in ... by the Pennsylvania Department of Community and Economic Development in 2016 as part of ... in the University City Keystone Innovation Zone and represent the highest number of awards ...
(Date:1/18/2017)... 18, 2017 /PRNewswire/ - SQI Diagnostics Inc. (TSX-V: ... company that develops and commercializes proprietary technologies and ... "Company"), today announced that Cameron Prange , ... resigned from its Board of Directors.  Mr. Prange,s ... regulations that have limited both his ability to ...
Breaking Biology Technology:
(Date:1/4/2017)...  CES 2017 – Valencell , the leading ... the launch of two new versions of its ... sensor modules that incorporate the best of Valencell,s ... The two new designs include Benchmark BE2.0, a ... Benchmark BW2.0, a 2-LED version of its original ...
(Date:12/22/2016)... SuperCom (NASDAQ:   SPCB ... e-Government, Public Safety, HealthCare, and Finance sectors announced today that Leaders ... to implement and deploy a community-based supportive services program to reduce ... , further expanding its presence in the state. ... This new program, which is expected ...
(Date:12/19/2016)... y TORONTO , 19 de diciembre de 2016 ... Inc. que permitirá el desarrollo acelerado de MSC-1, un anticuerpo humanizado ... tipos de tumor en 2017, con múltiples sitios previstos a lo ... ... objetivo en el factor inhibidor de leucemia (LIF), una citoquina pleiotrópica ...
Breaking Biology News(10 mins):